The EU may still have to wait to receive the hundreds of millions of doses of Covid-19 vaccine ordered from the German laboratory CureVac. On the evening of Wednesday 16 June, the company published inconclusive interim results on the effectiveness of its first-generation vaccine candidate (CVnCoV).
“In the unprecedented context of at least 13 variants circulating within the study population subset assessed at this interim analysis, CVnCoV demonstrated an interim vaccine efficacy of 47%...